Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of “Buy” by Brokerages

Nkarta, Inc. (NASDAQ:NKTXGet Rating) has received an average rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $45.75.

Several research analysts recently weighed in on the company. Raymond James assumed coverage on Nkarta in a research report on Friday, March 11th. They issued an “outperform” rating and a $17.00 price objective for the company. HC Wainwright assumed coverage on Nkarta in a research report on Tuesday, March 8th. They issued a “buy” rating and a $25.00 price objective for the company. Zacks Investment Research upgraded Nkarta from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, April 5th. William Blair initiated coverage on Nkarta in a research report on Thursday, January 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Nkarta in a research report on Tuesday, March 29th.

Several hedge funds and other institutional investors have recently made changes to their positions in NKTX. Wells Fargo & Company MN raised its stake in shares of Nkarta by 37.9% in the second quarter. Wells Fargo & Company MN now owns 8,032 shares of the company’s stock valued at $254,000 after acquiring an additional 2,207 shares in the last quarter. Morgan Stanley raised its stake in shares of Nkarta by 65.1% in the second quarter. Morgan Stanley now owns 158,126 shares of the company’s stock valued at $5,011,000 after acquiring an additional 62,376 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Nkarta by 222.3% in the third quarter. SG Americas Securities LLC now owns 17,090 shares of the company’s stock valued at $475,000 after acquiring an additional 11,788 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Nkarta in the third quarter valued at $1,134,000. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of Nkarta by 1,699,800.0% in the third quarter. Candriam Luxembourg S.C.A. now owns 67,996 shares of the company’s stock valued at $1,891,000 after acquiring an additional 67,992 shares in the last quarter. Institutional investors and hedge funds own 71.46% of the company’s stock.

NKTX stock opened at $8.79 on Friday. The business has a 50 day simple moving average of $10.32 and a 200-day simple moving average of $13.86. Nkarta has a 1 year low of $8.50 and a 1 year high of $40.64.

Nkarta (NASDAQ:NKTXGet Rating) last posted its quarterly earnings results on Thursday, March 17th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.06. Equities research analysts predict that Nkarta will post -3.07 EPS for the current fiscal year.

Nkarta Company Profile (Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Recommended Stories

Analyst Recommendations for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.